Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations
Ingvild Comfort Hvinden, Tom Cadoux‐Hudson, Christopher J. Schofield, James McCullagh
Abstract
mutations and discuss their clinical significance. We also review the metabolic effects of first-generation mutant IDH inhibitors and highlight the potential for combination treatment strategies and new metabolic targets.
Topics & Concepts
Isocitrate dehydrogenaseIDH1IDH2BiologyCarcinogenesisEnzymeMetabolic pathwayGeneMutantGeneticsCancer researchBiochemistryGlioma Diagnosis and TreatmentCancer, Hypoxia, and MetabolismCancer Genomics and Diagnostics